On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.
JPMorgan lowered the firm’s price target on AbbVie (ABBV) to $200 from $210 and keeps an Overweight rating on the shares. While the ...
Citi analyst Geoff Meacham lowered the firm’s price target on AbbVie (ABBV) to $215 from $226 and keeps a Buy rating on the shares. The ...
Zacks.com on MSN3d
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY GainsAbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback